Bank of America Securities Reaffirms Their Buy Rating on Danaher (DHR)
In a report released today, Michael Ryskin from Bank of America Securities maintained a Buy rating on Danaher, with a price target of $270.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ryskin covers the Healthcare sector, focusing on stocks such as Danaher, Idexx Laboratories, and Zoetis. According to TipRanks, Ryskin has an average return of 0.1% and a 47.68% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Danaher with a $233.74 average price target.
Based on Danaher’s latest earnings release for the quarter ending March 27, the company reported a quarterly revenue of $5.95 billion and a net profit of $1.03 billion. In comparison, last year the company earned a revenue of $5.74 billion and had a net profit of $954 million
Based on the recent corporate insider activity of 75 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DHR in relation to earlier this year. Earlier this month, Alan Spoon, a Director at DHR sold 1,358.00 shares for a total of $237,201.86.
Read More on DHR:
